Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
Anthony Elias(University of Colorado Cancer Center), Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Peter Kabos(University of Colorado Anschutz Medical Campus), Tessa McSpadden(University of Colorado Cancer Center), Elena Shagisultanova(University of Colorado Anschutz Medical Campus), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco), Lyndsey S. Crump(University of Colorado Cancer Center), Dexiang Gao(University of Colorado Cancer Center), Adrie van Bokhoven(University of Colorado Anschutz Medical Campus), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Angelo D’Alessandro(University of Colorado Anschutz Medical Campus), Alyse Staley(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Sharon B. Sams(University of Colorado Denver), Nicole S. Spoelstra(University of Colorado Anschutz Medical Campus), Gloria Crawford(Cancer Clinic), Gregory A. Vidal(West Cancer Center), Anosheh Afghahi(University of Colorado Anschutz Medical Campus), Kathryn L. Zolman(University of Colorado Anschutz Medical Campus), Yonghua Zhuang(University of Colorado Anschutz Medical Campus), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), José Mayordomo(Royal Bournemouth Hospital)
Cited by 16
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846